Tempest Therapeutics (TPST) Total Non-Current Liabilities (2011 - 2020)
Tempest Therapeutics (TPST) posted Total Non-Current Liabilities of $4.9 million for Q4 2020, little changed sequentially from $4.9 million in Q3 2020, and down 67.19% YoY from $15.1 million in Q1 2020.
Tempest Therapeutics (TPST) Total Non-Current Liabilities (2011 - 2020) Analysis & Trends
Tempest Therapeutics has reported Total Non-Current Liabilities for 10 years, with the latest figure at $4.9 million in Q4 2020.
- Quarterly Total Non-Current Liabilities fell 67.19% year-over-year to $4.9 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $4.9 million (down 67.19% YoY) and the FY2020 annual result came in at $4.9 million, down 67.19% from the prior year.
- Total Non-Current Liabilities was little changed at $4.9 million in Q4 2020 per TPST's latest filing, from $4.9 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $15.1 million in Q4 2019 and troughed at $3.9 million in Q3 2018.
- A 5-year average of $9.4 million and a median of $10.4 million in 2019 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2017 and 2019: Total Non-Current Liabilities slumped 69.13% in 2017, then jumped 245.81% in 2019.
- Over 5 years, Total Non-Current Liabilities stood at $13.2 million in 2016, then plunged by 69.13% to $4.1 million in 2017, then jumped by 150.12% to $10.2 million in 2018, then surged by 47.87% to $15.1 million in 2019, then plunged by 67.19% to $4.9 million in 2020.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $4.9 million, $4.9 million, and $12.2 million for Q4 2020, Q3 2020, and Q2 2020 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Tempest Therapeutics | 4.32 Mn | 3.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 4.95 Mn |
| Sep 30, 2020 | 4.95 Mn |
| Jun 30, 2020 | 12.19 Mn |
| Mar 31, 2020 | 13.40 Mn |
| Dec 31, 2019 | 15.08 Mn |
| Sep 30, 2019 | 13.42 Mn |
| Jun 30, 2019 | 13.07 Mn |
| Mar 31, 2019 | 10.43 Mn |
| Dec 31, 2018 | 10.20 Mn |
| Sep 30, 2018 | 3.88 Mn |
| Jun 30, 2018 | 4.75 Mn |
| Mar 31, 2018 | 5.03 Mn |
| Dec 31, 2017 | 4.08 Mn |
| Sep 30, 2017 | 8.90 Mn |
| Jun 30, 2017 | 11.82 Mn |
| Mar 31, 2017 | 10.59 Mn |
| Dec 31, 2016 | 13.21 Mn |
| Dec 31, 2015 | 11.24 Mn |
| Sep 30, 2015 | 9.86 Mn |
| Jun 30, 2015 | 7.60 Mn |